Ποια είναι η τιμή για AIkido Pharma Inc. (AIKI)

Η τιμή για AIkido Pharma Inc. (AIKI) είναι $3.56

Ποια είναι η κεφαλαιοποίηση αγοράς για AIkido Pharma Inc. (AIKI)

Η κεφαλαιοποίηση αγοράς για AIkido Pharma Inc. (AIKI) είναι $18.70M

AIkido Pharma Inc. (AIKI) Τιμή και Κεφαλαιοποίηση Αγοράς

AIkido Pharma Inc., established in 1967 and headquartered in New York, New York, is a biotechnology company primarily engaged in pioneering small-molecule anti-cancer treatments. The firm, which operated as Spherix Incorporated until its rebranding in March 2021, possesses a robust therapeutic pipeline addressing various malignancies, including prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. Key drug candidates in its development portfolio include DHA-dFdC, targeting pancreatic cancer, and KPC34, a small molecule designed for the treatment of both AML and acute lymphoblastic leukemia. Furthermore, AIkido Pharma Inc. is advancing an antiviral platform engineered to hinder the proliferation of numerous viruses, such as the influenza virus, Ebolavirus, Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. The company holds strategic license agreements with several academic and research institutions, including the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences.

Η τιμή για AIKI	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$1,010,285 $18.70M	NVDA	$5.307T	+28,378,698.94%
$866,384 $18.70M	AAPL	$4.551T	+24,336,533.34%
$790,922 $18.70M	GOOG	$4.154T	+22,216,814.51%
$683,200 $18.70M	MSFT	$3.589T	+19,190,911.09%
$532,473 $18.70M	AMZN	$2.797T	+14,957,018.94%

Η τιμή για AIKI

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$1,010,285 $18.70M